Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 14/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1011640 | 0.86 | LMNA (0.46) | MCHR1KCNH2LMNACYP1A2PTGS1 | |
| SCHEMBL1013518 | 0.85 | S1PR5 (0.38) | — | |
| SCHEMBL23883437 | 0.79 | ROCK1 (0.44) | MCHR1LMNA | |
| SCHEMBL30335520 | 0.79 | ROCK1 (0.44) | MCHR1LMNA | |
| SCHEMBL30335333 | 0.77 | KCNH2 (0.42) | KCNH2CYP1A2CYP2C19 | |
| SCHEMBL23883491 | 0.77 | KCNH2 (0.42) | KCNH2CYP1A2CYP2C19 | |
| SCHEMBL1727591 | 0.74 | MAOB (0.36) | MAOB | |
| SCHEMBL5734440 | 0.74 | ROCK1 (0.58) | MCHR1KCNH2HRH3 | |
| SCHEMBL2837205 | 0.74 | ROCK1 (0.57) | MCHR1KCNH2BCHELMNACYP1A2 | |
| SCHEMBL1014177 | 0.72 | ROCK1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012009617-A3 | METHODS, STORAGE MEDIUMS, AND SYSTEMS FOR ANALYZING PARTICLE QUANTITY AND DISTRIBUTION WITHIN AN IMAGING REGION OF AN ASSAY ANALYSIS SYSTEM AND FOR EVALUATING THE PERFORMANCE OF A FOCUSING ROUTING PERFORMED ON AN ASSAY ANALYSIS SYSTEM | LUMINEX CORPORATION (US) | 2012-05-10 | — | — | WO | disclosed |
| EP-2271617-B1 | SUBSTITUTED 4-HYDROXY-N- (4-HYDROXYPHENYL) INDOLES AS ESTROGENIC AGENTS | GLAXO GROUP LTD (GB) | 2011-11-30 | — | — | EP | disclosed |
| US-7956083-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2011-06-07 | — | — | US | disclosed |
| US-7956083-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2011-06-07 | — | — | US | disclosed |
| US-7956083-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2011-06-07 | — | — | US | disclosed |
| EP-2271617-A1 | SUBSTITUTED 4-HYDROXY-N- (4-HYDROXYPHENYL) INDOLES AS ESTROGENIC AGENTS | Glaxo Group Limited (GB) | 2011-01-12 | — | — | EP | disclosed |
| US-20100324106-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | US | disclosed |
| US-20100324106-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | US | disclosed |
| US-20100324106-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | US | disclosed |
| WO-2009103710-A1 | SUBSTITUTED 4-HYDROXY-N- (4-HYDROXYPHENYL) INDOLES AS ESTROGENIC AGENTS | GLAXO GROUP LIMITED (GB) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324106-A1 | COMPOUNDS | ESR2, GPER1, ESR1 | MCHR1 537/4885KCNH2 3181/4885HRH3 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.